New UPLIZNA? (inebilizumab-cdon) Data in People With Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the American Academy of Neurology?s 73rd Annual Meeting
DUBLIN--(BUSINESS WIRE)--Apr. 5, 2021--?Horizon Therapeutics plc?(Nasdaq: HZNP) today announced new UPLIZNA (inebilizumab-cdon) data will be presented at the?American Academy?of Neurology?s 73rd Annual Meeting, which will be held virtually?April 17-22, 2021. UPLIZNA is the first and only FDA-approved B-cell depleter for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positive NMOSD.
UPLIZNA data being presented at AAN 2021 include:
- Inebilizumab Treatment Reduces the Occurrence of Pain in NMOSD Patients
- Session:?P2.017,?H. Kim
- Date:?On Demand (scientific poster)
- Long-Term Efficacy Outcomes with Inebilizumab Treatment in NMOSD: the N-MOmentum Trial
- Session:?P15.076,?B. Cree
- Date:?On Demand (scientific poster)
- Long-Term Safety Outcomes with Inebilizumab Treatment in NMOSD: the N-MOmentum Trial
- Session:?P15.100,?B. Cree
- Date:?On Demand (scientific poster)
- Evaluation of Infusion Reactions and Infusion Times in the N-MOmentum Study of Inebilizumab for NMOSD
- Session:?P15.211,?M. Tullman
- Date:?On Demand (scientific poster)
- Pharmacodynamic Modeling and Exposure-Response Assessment of Inebilizumab in Subjects With Neuromyelitis Optica Spectrum Disorder
- Session:?S29.003,?L. Yan
- Date:?Wednesday, April 21, 2021,?4:24 p.m. ET?(live broadcast)
- Patient Attitudes Towards NMOSD Diagnosis and Treatment: Final Survey Results
- Session:?P2.106,?G. Garcia
- Date:?On Demand (scientific poster)
- A history of life-threatening infusion reaction to?UPLIZNA
- Active hepatitis B infection
- Active or untreated latent tuberculosis
- Ajmera MR, Boscoe A, Mauskopf J, Candrilli SD, Levy M. Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica.?J Neurol Sci. 2018; 384:96-103.
- What is NMO??Guthyjacksonfoundation.org.?www.guthyjacksonfoundation.org/neuromyelitis-optica-nmo/?Accessed?March 9, 2020.
- Layman?s Guide to NMO.?Sumairafoundation.org.?https://www.sumairafoundation.org/laymans-guide-to-nmo/?Accessed?March 9, 2020.
- Liu Y, et al. A tract-based diffusion study of cerebral white matter in neuromyelitis optica reveals widespread pathological alterations.?Mult Scler. 2011;18(7);1013-1021.
- Duan T, Smith AJ, Verkamn AS. Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxity.?Acta Neuropathologica Comm. 2019;7(112)
- Beekman J, et al. Neuromyelitis optica spectrum disorder: patient experience and quality of life. Neural Neuroimmunol Neuroinflamm. 2019;6(4):e580
- Kimbrough DJ, et al. Treatment of neuromyelitis optica: review and recommendations.?Mult Scler Relat Disord.?2012;1(4):180-187.
- Baranello RJ, Avasarala, JR. Neuromyelitis optica spectrum disorders with and without aquaporin 4 antibody: Characterization, differential diagnosis, and recent advances.?J Neuro Ther.?2015;1(1):9-14.
- Wingerchuk DM. Neuromyelitis optica: effect of gender.?J Neurol Sci.?2009;286(1-2):18-23
- Flanagan EP, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum.?Ann Neurol.?2016;79(5):775-783.
View source version on?businesswire.com:?https://www.businesswire.com/news/home/20210405005089/en/
Tina Ventura Senior Vice President, Investor Relations Investor-relations@horizontherapeutics.com Ruth Venning Executive Director, Investor Relations Investor-relations@horizontherapeutics.com U.S.?Media Contacts: Rachel Vann Director,?Product Communications media@horizontherapeutics.com Ireland Media Contact: Gordon MRM Ray Gordon ray@gordonmrm.ie Source:?Horizon Therapeutics plc